Form 4: Protara CFO Fabbio Expands Stake with New Equity Awards

Protara Therapeutics' Chief Financial Officer, Patrick Fabbio, acquired 28,000 restricted stock units and options for 175,000 shares of common stock as part of his compensation.

Summary

• Patrick Fabbio, Chief Financial Officer of Protara Therapeutics, Inc. (TARA), acquired 28,000 shares of common stock through Restricted Stock Unit (RSU) awards.
• Fabbio also acquired options to purchase 175,000 shares of common stock with an exercise price of $5.01 per share.
• Both transactions occurred on January 16, 2026.
• The RSUs vest in equal one-third installments on the first, second, and third anniversaries of January 16, 2026, contingent on continuous service.
• The stock options vest 25% on the one-year anniversary of January 16, 2026, and then 1/48th monthly over the subsequent three years, also contingent on continuous service.
• Following these transactions, Fabbio beneficially owns 70,439 shares of common stock directly and 175,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive due to increased management alignment with shareholder interests through equity awards, which incentivizes long-term performance and retention. This is a routine compensation event.

Positives

• Increased alignment of management's interests with shareholders through significant equity awards.
• Equity compensation incentivizes long-term performance and retention of key executives.

Negatives

• Potential for future minor dilution of existing shareholders as RSUs vest and options are exercised.

Risks

• The value of the equity awards is subject to the future performance of Protara Therapeutics' stock price.
• Vesting conditions require continuous service, meaning the awards could be forfeited if employment ceases.

Future Outlook

The vesting schedules for both the RSUs and stock options extend over several years, indicating an expectation of continued service from the Chief Financial Officer and a long-term incentive structure tied to the company's future performance.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent. This aligns the interests of executives with long-term shareholder value creation.

Comparison to Industry Standards

• This type of equity grant, with multi-year vesting schedules, is a common and widely accepted form of executive compensation across the biotech and broader public company landscape.
• It is consistent with practices seen at comparable small to mid-cap biopharmaceutical companies, aiming to retain key personnel and align their incentives with long-term company performance.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting and exercise of awards, but also increased alignment of management's interests with long-term shareholder value.

Next Steps

• Continued service of Patrick Fabbio with Protara Therapeutics, Inc.
• Vesting of RSUs on the first, second, and third anniversaries of January 16, 2026.
• Vesting of stock options, with 25% on the one-year anniversary and monthly thereafter over three years.

Key Dates

Keywords

Protara Therapeutics, TARA, Patrick Fabbio, Chief Financial Officer, CFO, SEC Form 4, insider transaction, equity compensation, restricted stock units, RSUs, stock options, beneficial ownership, executive compensation